In a cautiously worded essay, the Food and Drug Administration commissioner and more than a dozen other agency officials are trying to temper enthusiasm for a controversial provision in the 21st Century Cures Act, which was signed into law on Tuesday by President Obama.

The subject of their treatise is real-world evidence, a euphemism for various sorts of data that the law would allow the agency to use for approving additional uses of medicines, as well as for any follow-up studies that may be required. Such evidence could include electronic health records, observational studies, ongoing safety monitoring, claims data, and patient registries, among other things.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Skip this whole “efficacy” nonsense for drug approval, “safety” (doesn’t kill you within, let’s say, 3 weeks) is good enough! GREAT! again…

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy